US Pharma MarketingGalmed Pharmaceuticals acquired Colospan in a $4.5 million million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion.
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: FierceBiotech